TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares traded -2.25% lower at $0.45 on Wall Street last session.
In accordance with the data, 1 analysts cover TC Biopharm (Holdings) Plc (NASDAQ:TCBP). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.61 and a low of $5.61, we find $5.61. Given the previous closing price of $0.46, this indicates a potential upside of 1119.57 percent. TCBP stock price is now -42.14% away from the 50-day moving average and -90.57% away from the 200-day moving average. The market capitalization of the company currently stands at $1.18M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $5.61 as their price target over the next twelve months.
In other news, Randall Diana Elizabeth, 10% Owner bought 70,000 shares of the company’s stock on Nov 30. The stock was bought for $350,000 at an average price of $5.00. Upon completion of the transaction, the 10% Owner now directly owns 70,000 shares in the company, valued at $31500.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 30, 10% Owner Randall Kenneth Edward bought 70,000 shares of the business’s stock. A total of $350,000 was incurred on buying the stock at an average price of $5.00. This leaves the insider owning 382,963 shares of the company worth $0.17 million. A total of 11.74% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TCBP stock. A new stake in TC Biopharm (Holdings) Plc shares was purchased by WELLS FARGO & COMPANY/MN during the first quarter worth $3,000. STEWARD FINANCIAL GROUP LLC invested $1,000 in shares of TCBP during the first quarter. In total, there are 3 active investors with 12.40% ownership of the company’s stock.
TC Biopharm (Holdings) Plc (NASDAQ: TCBP) opened at $0.4780 on Monday. During the past 12 months, TC Biopharm (Holdings) Plc has had a low of $0.45 and a high of $22.00. The fifty day moving average price for TCBP is $0.7550 and a two-hundred day moving average price translates $4.6627 for the stock.
The latest earnings results from TC Biopharm (Holdings) Plc (NASDAQ: TCBP) was released for Dec, 2022. The net profit margin was -36.10% and return on equity was 19.70% for TCBP.
TC Biopharm (Holdings) Plc(TCBP) Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
